Switch to icatibant in a patient affected by hereditary angioedema with high disease activity: a case report.

Abstract

Icatibant, an antagonist of the bradykinin B2 receptor, was approved for the treatment of acute attacks of hereditary angioedema in the EU in 2008. This paper presents the case of a 65-year-old woman affected by frequent acute attacks of hereditary angioedema who benefitted from a change of therapy to icatibant, following years of treatment with C1-inhibitor.

• Authors: D Firinu, M P Barca, L Serusi, M M Lorrai, M M Peralta, P E Manconi, S R Del Giacco
• Journal: International journal of immunopathology and pharmacology (Int J Immunopathol Pharmacol) 2012 Jan-Mar Vol. 25 Issue 1 Pg. 269-73 ISSN: 0394-6320 [Print] England
• PMID: 22507340 (Publication Type: Case Reports, Letter, Research Support, Non-U.S. Gov't)

Chemical References

• Bradykinin B2 Receptor Antagonists
• Complement C1 Inhibitor Protein
• icatibant
• Bradykinin

Topics

• Aged
• Angioedemas, Hereditary (drug therapy)
• Bradykinin (analogs & derivatives, therapeutic use)
• Bradykinin B2 Receptor Antagonists
• Complement C1 Inhibitor Protein (analysis, therapeutic use)
• Female
• Humans